Disclosed are an IL-5 binding molecule, and a preparation method and use thereof. The binding molecule includes the following complementarity determining regions: an amino acid sequence of CDR1 selected from any one of sequences as set forth in SEQ ID NOs. 43-49; an amino acid sequence of CDR2 selected from any one of sequences as set forth in SEQ ID NOs. 50-56; and an amino acid sequence of CDR3 selected from any one of sequences as set forth in SEQ ID NOs. 57-62. The binding molecule is capable of specifically binding to IL-5, and effectively blocking the cell proliferation induced by IL-5.

Compositions comprising donor cells, acceptor cells, membrane-enclosed bodies and methods are described herein.

The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.

The present disclosure provides methods and systems for cell and bead processing or analysis. A method for processing a cell or bead may include subjecting a bead to conditions sufficient to change a first characteristic or set of characteristics (e.g., cell or bead size). Such a method may further include subjecting the cell or bead to conditions sufficient to change a second characteristic or set of characteristics. In some cases, crosslinks may be formed within the cell or bead.

Compositions for and methods of manufacturing a fucosylated cell population are provided. The method may include expansion of the cells and/or cryopreservation of the cells under conditions that retain optimum levels of cell surface fucosylation.

The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.

A factor that is caused by a nucleic acid and influences the kinetics of an extracellular vesicle is screened. A library of barcoded extracellular vesicles is provided.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

A method for coupling an antibody to a surface of a cell comprises the following steps: (1) chemically modifying sialic acid to obtain a sialic acid derivative containing an azide group; (2) absorbing the sialic acid derivative by the cell to obtain a cell modified with the azide group; (3) modifying the antibody with a conjunction compound to obtain a modified antibody; (4) co-culturing the modified antibody with the cell modified with the azide group. The present disclosure modifies natural sialic acid molecules in vitro through chemical synthesis methods, and utilizes modified natural sialic acid molecules to realize antibody modification on the surface of the cell. The modification method of the present disclosure is simple, low-cost, safe, and efficient, does not need complex gene editing or enzyme catalytic operation, and has universality. In theory, the modification method can realize the coupling of any antibody or macro-molecular substance on the surface of the cell.

Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to non-genetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g., for diagnostic and/or therapeutic purposes, are provided.